Overview

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections including EVR, ETR, and SVR.

Phase:

Phase 2

Details

Lead Sponsor:

GlobeImmune

Treatments:

Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin